Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Therapy With Paclitaxel, Carboplatin and Megesterol Acetate for the Management of Uterine Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have biopsy proven endometrioid adenocarcinoma or adenosquamous carcinoma.~* Patients must have evidence of primary FIGO Stage III-IVB or recurrent endometrial cancer.~* Patients with non-measurable disease following complete cytoreduction at the time of initial operative management for Stage III-IVB are eligible.~* Patients with recurrent disease must have disease confirmed by one of the following:~  1. CT Scan~ 2. MRI~ 3. PET Scan~ 4. Physical Exam~* Patients must have adequate organ function defined as:~  1. Platelets \>/= 100,000/1~ 2. Granulocytes (ANC) \>/= 1,500/~ 3. Creatinine \</= 1.6mg/dl~ 4. SGOT (AST) \</= 3x upper limits of normal~ 5. Bilirubin within institutional normal limits~* Patients must have adequate performance status (ECOG performance status 0-2.~* Patients must be age 19 or greater and have signed informed consent.~Exclusion Criteria:~* Patients with history of other malignancies (except non-melanoma skin cancer or carcinoma-in-situ of the cervix) are ineligible.~* Patients with high-risk histologic subtypes of endometrial cancer, namely papillary serous or clear cell histology are ineligible.~* Patients with evidence of uterine sarcoma, including leiomyosarcoma, carcinosarcoma, endometrial stromal sarcoma, and adenosarcoma are ineligible.~* Patients who are less than 8 weeks after the completion of radiotherapy are ineligible.~* Patients receiving any other investigational agents are ineligible.~* Patients with known hypersensitivity to paclitaxel, carboplatin, or megesterol are ineligible.~* Patients with uncontrolled current illness including, but not limited to, ongoing or active infection, unstable angina pectoris, cardiac arrhythmia, serious peripheral neuropathy, or psychiatric illness/social situations that would limit or preclude compliance with study requirements are ineligible.

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chemotherapy (Type: EXPERIMENTAL): Single

Based on this trial design, predict the completion outcome and termination type (if applicable).